Deficiency of factor-inhibiting HIF creates a tumor-promoting immune microenvironment

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Hypoxia signaling is crucial in tumor development via intrinsic and extrinsic pathways.
• Inhibiting hypoxia-inducible factor (HIF) is an emerging cancer treatment strategy.
• Understanding HIF regulators' physiological roles is vital for cancer research.

Purpose of the Study:

• To investigate the role of factor-inhibiting HIF (FIH) as a regulator of spontaneous tumor development in aging mice.
• To determine how FIH deficiency impacts immune composition and the tumor microenvironment.
• To elucidate the mechanisms by which FIH influences tumorigenesis.

Main Methods:

• Analysis of spontaneous B cell lymphomas in aging mice with varying FIH levels.
• Characterization of immune cell composition in aged mice with FIH deficiency.
• Utilizing syngeneic mouse tumor models to assess the impact of FIH-defective myeloid cells on tumor growth.

Main Results:

• FIH acts as a haploinsufficient suppressor of spontaneous B cell lymphomas, particularly pulmonary lymphomas, in aging mice.
• FIH deficiency leads to altered immune composition and a tumor-supportive immune environment.
• FIH-defective myeloid cells exhibit enhanced arginase expression and cytokine-directed migration, acquiring tumor-supportive properties.

Conclusions:

• FIH plays a critical role in maintaining immune homeostasis under physiological conditions.
• FIH suppresses tumorigenesis through a cell-extrinsic pathway involving immune modulation.
• Targeting FIH or its downstream pathways could offer novel cancer treatment strategies.